Polychondritis is chronic disease characterized by inflammation and destruction of the cartilage of various tissues of the body. The cause of polychondritis is unknown, but the disease may be the result of an abnormal immune response. Symptoms include pain, redness, and swelling of the affected cartilage. polychondritis begins in middle age and most often affects the external ear, nose, and joints. Involvement of the trachea may obstruct breathing or lead to pneumonia. Moreover, polychondritis also may affect the inner ear and cause deafness, or it may cause inflammation of the eyes. Corticosteroid medications are administered to moderate the symptoms of the disease, but the effects on the cartilage cannot be reversed.
Impact of COVID-19 on Polychondritis Disease Treatment Market
Coronavirus disease 2019 (COVID-19) has created an economic crisis along with a health care crisis. COVID-19 pandemic has stretched healthcare system worldwide, developed countries are expected to cause economic recession. The COVID-19 pandemic has had a considerable effect on different aspects of rare and complex diseases, first on the risk of SARS-CoV-2 infection for people affected by these conditions, and also on the management of care and treatment during (and after) this global health emergency. The preliminary results of a Europe-wide survey organized by Rare Barometer (an initiative of the European Organisation for Rare Diseases), which was aimed at collecting the opinions, experiences and needs of patients with rare diseases, highlighted the many challenges faced by these patients as well as their families and caregivers during the pandemic, including the interruption of routine medical care and rehabilitation therapies as well as many psychological barriers related both to isolation and to fear of infection with SARS-CoV-2 when receiving care in hospitals. These same challenges can be readily related to polychondritis disease, in which the rate and mechanisms of COVID-19 transmission have raised many concerns among scientists and patients, especially considering the well-known susceptibility of these patients to infections owing to their altered immune systems and to the use of immunosuppressive therapies.
Top impacting factors: market scenario analysis, trends, drivers and impact analysis
Increasing investments in R&D in pharmaceutical and life sciences sectors is the vital factor escalating the market growth, also rise in the availability of various alternatives for treatment, rise in the awareness about autoimmune diseases among consumers, large patient base, rise in the healthcare expenditures and rise in the research and development activities are the major factors among others driving the polychondritis disease treatment market. Moreover, rise in the technological advancement and modernization in the healthcare devices and rise in the demand from emerging economies will further create new opportunities for polychondritis disease treatment market in the forecasted period. However, lack of skilled technicians and rise in the dearth of understanding regarding the basic etiology of various autoimmune diseases are the major factors among others which will obstruct the market growth, and will further challenge the growth of polychondritis disease treatment market in the forecast period.
Key benefits of the report
- This study presents the analytical depiction of the global polychondritis disease treatment market along with the current trends and future estimations to determine the imminent investment pockets.
- The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the polychondritis disease treatment market share.
- The current market is quantitatively analyzed to highlight the polychondritis disease treatment market growth scenario.
- Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
- The report provides a detailed market analysis depending on competitive intensity and how the competition will take shape in coming years.
Questions answered in the polychondritis disease treatment market report
- Which are the leading players active in the polychondritis disease treatment market?
- What are the current trends that will influence the market in the next few years?
- What are the driving factors, restraints, and opportunities of the market?
- What are the projections for the future that would help in taking further strategic steps?
Polychondritis Disease Treatment Market Report Highlights
| Aspects | Details |
 By Diagnosis |
|
 By Treatment |
|
 By Mode of Administration |
|
 By Distribution Channel |
|
 By Region |
|
 Key Market Players | Mallinckrodt company., Pfizer Inc., Regeneron Pharmaceuticals Inc., Allergan, Novartis AG, Johnson & Johnson Private Limited, AbbVie Inc., Swedish Orphan Biovitrum AB., Bausch Health Companies Inc., Abbott. |
Loading Table Of Content...
